GLAXF News and Press, GlaxoSmithKline Plc From 06/16/20

Computational Biology: An Emerging Industry Coming Into Its Own The legendary investor Phil Fisher was notable for identifying companies with exceptional long-term growth characteristics, buying shares and holding for an extremely long time. In his excellent book, Common Stocks and Uncommon ...

This article is part of a series that provides an ongoing analysis of the changes made to Ariel Investments’ 13F stock portfolio on a quarterly basis. It is based on Ariel Investments’ regulatory 13F Form filed on 05/14/2020. John Rogers’ 13F portfolio value decreased ~3...

This article is part of a series that provides an ongoing analysis of the changes made to Tweedy, Browne's 13F portfolio on a quarterly basis. It is based on Tweedy, Browne's regulatory 13F Form filed on 05/13/2020. Please visit our Tracking Tweedy, Browne Portfolio series to get an idea o...

Musings May’s risk-on environment baffled many (and again caused soul searching amongst dividend and value investors. How long can factors (which has proven to create alpha over long stretches of time) continue to lag the market? As John Maynard Keynes aptly phrased it, ȁ...

Quick Take Vaxcyte ( PCVX ) intends to raise $210 million in an IPO of its ordinary shares, per an amended registration statement . The company is developing a family of vaccines for pneumococcal and other global markets. PCVX is a very early stage, preclinical vaccine researcher and th...

GlaxoSmithKline plc (NYSE: GSK ) has bounced back nicely after COVID-19 sell-off, though over 3 years, still underperformed most peers. Data by YCharts Thanks to COVID-19, the company delivered solid Q1 results, but the 2020 guidance was confirmed as we should expect reversals in the n...

Vir Bio Moves Ahead with COVID Projects, Reports Higher Q1 Revenue Vir Biotechnology ( VIR ) provided an update about its COVID projects, while confirming GlaxoSmithKline's ( GSK ) investment worth $250 million. The company is currently working on multiple clinical programs to address C...

This article is part of a series that provides an ongoing analysis of the changes made to Kahn Brothers' 13F stock portfolio on a quarterly basis. It is based on Kahn Brothers' regulatory 13F Form filed on 05/11/2020. Please visit our Tracking Kahn Brothers Portfolio series to get an idea ...

Orchard Therapeutics ( ORTX ) is an undercovered, $1.7bn London-headquartered company positioning itself to be the market leader in next-generation, cryopreserved, easily accessible, lentiviral vector based gene therapy. The company originally had 2 gene therapy assets. In 2018, Orchard Therap...

Quick Take ADC Therapeutics ( ADCT ) intends to raise $125 million from the sale of its common stock, per an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of blood cancers and solid tumors. ADCT is making a new attempt to go pu...